Pharmacogenetics and immunosuppressive drugs in solid organ transplantation

T Van Gelder, RH Van Schaik… - Nature Reviews …, 2014 - nature.com
The transplantation literature includes numerous papers that report associations between
polymorphisms in genes encoding metabolizing enzymes and drug transporters, and …

Mycophenolate revisited

T van Gelder, DA Hesselink - Transplant International, 2015 - Wiley Online Library
The patent of mycophenolate mofetil (MMF) has expired, and for enteric‐coated
mycophenolate sodium (EC‐MPS), this will happen in 2017. In the twenty years these drugs …

[HTML][HTML] A randomized controlled trial comparing the efficacy of Cyp3a5 genotype‐based with body‐weight‐based tacrolimus dosing after living donor kidney …

N Shuker, R Bouamar, RHN van Schaik… - American Journal of …, 2016 - Elsevier
Patients expressing the cytochrome P450 (CYP) 3A5 gene require a higher tacrolimus dose
to achieve therapeutic exposure compared with nonexpressers. This randomized‐controlled …

The combination of CYP3A4* 22 and CYP3A5* 3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation

N Lloberas, L Elens, I Llaudó, A Padullés… - Pharmacogenetics …, 2017 - journals.lww.com
Results EM had an 88% lower dose-adjusted C 0 compared with IM. PM had a 26% higher
dose-adjusted C 0 compared with IM. The percentage of patients with supratherapeutic Tac …

Which genetic determinants should be considered for tacrolimus dose optimization in kidney transplantation? A combined analysis of genes affecting the CYP3A locus

H Bruckmueller, AN Werk, L Renders… - Therapeutic drug …, 2015 - journals.lww.com
Background: Tacrolimus is established as immunosuppressant after kidney transplantation.
Polymorphism of the cytochrome P450 3A5 (CYP3A5) gene contributes significantly to …

Dosing algorithms for initiation of immunosuppressive drugs in solid organ transplant recipients

LM Andrews, N Riva, BC de Winter… - Expert opinion on …, 2015 - Taylor & Francis
Introduction: Starting doses of tacrolimus and ciclosporin are typically chosen on a
calculated mg/kg bodyweight basis. After initiation of treatment, doses are adjusted with …

Impact of single nucleotide polymorphisms (SNPs) on immunosuppressive therapy in lung transplantation

J Ruiz, MJ Herrero, V Bosó, JE Megías… - International Journal of …, 2015 - mdpi.com
Lung transplant patients present important variability in immunosuppressant blood
concentrations during the first months after transplantation. Pharmacogenetics could explain …

Pharmacogenomic implications of population admixture: Brazil as a model case

G Suarez-Kurtz, DP Paula, CJ Struchiner - Pharmacogenomics, 2014 - Taylor & Francis
The heterogeneous Brazilian population, with European, African and Amerindian ancestral
roots is a model case for exploring the impact of population admixture on the frequency …

Influence of IL‐18 and IL‐10 polymorphisms on tacrolimus elimination in Chinese Lung Transplant Patients

X Zhang, J Xu, J Fan, T Zhang, Y Li, B Xie… - Disease …, 2017 - Wiley Online Library
Aims. The influence of interleukin‐10 (IL‐10) and interleukin‐18 (IL‐18) polymorphisms on
tacrolimus pharmacokinetics had been described in liver and kidney transplantation. The …

Genomewide association study reveals novel genetic loci associated with change in renal function in heart transplant recipients

R Asleh, D Snipelisky, M Hathcock… - Clinical …, 2018 - Wiley Online Library
Background Renal dysfunction occurs commonly after heart transplantation (HT x) with wide
inter‐individual variability but whether a genetic predisposition exists in these patients is …